Standout Papers
Citation Impact
Citing Papers
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
2012
PI3Kδ Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic
2011
PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
2012
Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
2014
Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling
2011
PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines
2013
Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
2012
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
2018
A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
2012
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
2018
Comprehensive genomic characterization of head and neck squamous cell carcinomas
2015 StandoutNature
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
2020
Breast cancer
2019 Standout
Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations
2018
Immunotherapy and targeted therapy combinations in metastatic breast cancer
2019
Src: a potential target for the treatment of triple-negative breast cancer
2011
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
2011
Head and neck squamous cell carcinoma
2020 Standout
The PI3K/AKT Pathway as a Target for Cancer Treatment
2015
Breast cancer statistics, 2019
2019 Standout
Treatment of rats with the peroxisome proliferator ciprofibrate results in increased liver NF-kB activity
1996
Activators and target genes of Rel/NF-κB transcription factors
1999 Standout
Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor
2014 StandoutNobel
A view on drug resistance in cancer
2019 StandoutNature
Breast cancer
2016 Standout
Controversies around epithelial–mesenchymal plasticity in cancer metastasis
2019
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
2014
Ovarian cancer
2014 Standout
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Predicting treatment resistance and relapse through circulating DNA
2017
Cushing's syndrome
2015 Standout
Nomograms in oncology: more than meets the eye
2015 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
2016
Hepatocellular carcinoma
2021 Standout
Colorectal Cancer Stem Cells: From the Crypt to the Clinic
2014
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Nano based drug delivery systems: recent developments and future prospects
2018 Standout
The landscape of long noncoding RNAs in the human transcriptome
2015 Standout
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
2013
Drug repurposing: progress, challenges and recommendations
2018 Standout
Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs
2011
Unraveling the therapeutic potential of the Hedgehog pathway in cancer
2013 Standout
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
2015
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
Treatment for the endocrine resistant breast cancer: Current options and future perspectives
2017
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
2012
CDK4/6 inhibition triggers anti-tumour immunity
2017 Nature
EMT: 2016
2016 Standout
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
2014 Standout
The molecular landscape of head and neck cancer
2018 Standout
Emerging landscape of oncogenic signatures across human cancers
2013
AKT/PKB Signaling: Navigating the Network
2017 Standout
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
The PI3K Pathway in Human Disease
2017 Standout
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
2015
Renal cell carcinoma
2017 Standout
Cervical cancer
2019 Standout
The prognostic landscape of genes and infiltrating immune cells across human cancers
2015 Standout
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
2013
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
Role of hypoxia in inhibiting dendritic cells by VEGF signaling in tumor microenvironments: mechanism and application.
2021
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
2015
p53-Mediated Repression of Alpha-Fetoprotein Gene Expression by Specific DNA Binding
1999
The Safety of Ovarian Preservation in Early-Stage Adenocarcinoma Compared With Squamous Cell Carcinoma of Uterine Cervix
2016
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Cdk2 is Required for Breast Cancer Mediated by the Low-Molecular-Weight Isoform of Cyclin E
2011
Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
2016
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
Somatic mutation in PIK3CA is a late event in cervical carcinogenesis
2015
Nomogram to Predict Cycle-One Serious Drug-Related Toxicity in Phase I Oncology Trials
2014
Breast Cancer Treatment
2019 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
2015
A Direct Intersection between p53 and Transforming Growth Factor β Pathways Targets Chromatin Modification and Transcription Repression of the α-Fetoprotein Gene
2005
Transcriptional control of human p53-regulated genes
2008 Standout
Molecular Docking: Shifting Paradigms in Drug Discovery
2019 Standout
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
2020
Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches
2016 Standout
Current Status of Src Inhibitors in Solid Tumor Malignancies
2011
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS
2005 Standout
Analysis of nanoparticle delivery to tumours
2016 Standout
Adrenocortical Carcinoma
2013
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies
2016
Clinical Translation of Nanomedicine
2015
Atomically Precise Clusters of Noble Metals: Emerging Link between Atoms and Nanoparticles
2017 Standout
Works of Stacy Moulder being referenced
Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors
2010
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
2011
Weekly nab -Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
2013
Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy
2010
Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
2014
Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit
2014
A Sensitive lacZ -Based Expression Vector for Analyzing Transcriptional Control Elements in Eukaryotic Cells
1995
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
2014
A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis
2018
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Metaplastic Breast Cancer: Clinical Overview and Molecular Aberrations for Potential Targeted Therapy
2015
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
2012
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience
2012
PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes
2012
A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.
2010
A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice
2014
A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies
2011
PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC).
2016
Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies
2009